Trending now
Anas Younes, M.D.
Medical oncologist/scientist. Former Chief of Lymphoma at MSKCC. Working on changing treatment outcome for patients with blood cancers. Now SVP at AstraZeneca.
Catching up on scientific readings, proofing abstracts for EHA and Lugano, and coffee!
The obligatory stop and shop at a local bookstore during international travels. Always discover new good books! Can you tell which ones I bought?
#March8th is/was International Women’s Day, and I am thrilled to be celebrating amongst our colleagues. Equality and equity in #STEM are essential to driving innovation, and I believe we each have a role in building a world where women have equitable acce…
It was a pleasure being a guest on @HealthProRadio to discuss our ambitions at @AstraZeneca on changing the future of the #hematology treatment paradigm by advancing current discoveries. Hear more about our vision for some of the latest …
Always a pleasure to see former @MSKCancerCenter colleagues to catch up on the great work they do to improve treatment outcome for cancer patients
It's official! I will be joining an MSKCC alumni team from @AstraZenecaUS at @Cycle4Survival to raise money for rare cancer research at @MSKCancerCenter . You can help build a better future for people worldwide.
Loading
Less is better in DLBCL: Two studies showed 4 is as good as 6 cycles of RCHOP in early stage non bulky good risk patients, and 6 is as good as 8 cycles of RCHOP in advanced stage DLBCL #ASH18
Reading through the many #ASH22 AML abstracts: despite the excellent scientific advances reported in recent years, this has not translated into new transformative medicines, and the OS remains poor. AML remains a major area with unmet medical needs. More innovation is needed!
Sad to hear about the passing of prof Ton Hagenbeek of the Academic Medical Center, Univ of Amsterdam. Ton was a world class expert on lymphoma and made many contributions to advance the field. His well balanced views were respected by colleagues from around the world. RIP
Impressive results in relapsed HL using brentuximab vedotin plus nivolumab. A randomized trial comparing this regimen with standard BV is enrolling patients at #ASH17
Loading